Group 1 - The innovative drug sector is experiencing a rebound due to favorable policy news, with the Hang Seng Innovative Drug ETF (520500) seeing active trading [1] - The National Medical Products Administration announced a 30-day approval channel for innovative drug clinical trials, effective September 12, 2025, aimed at optimizing the review process [1] - Despite recent overseas restrictive policy rumors affecting market sentiment, there is strong capital inflow into the ETF, indicating resilience in market confidence [1] Group 2 - On September 11, 2025, the Hang Seng Innovative Drug ETF (520500) received 127 million yuan in capital inflow, with a total trading volume of 1.548 billion yuan, reflecting a 94% increase [1] - The ETF tracks the Hang Seng Innovative Drug Index, which focuses on high-growth Hong Kong-listed companies involved in drug research, development, and production [1] - The index was revised on August 11, 2025, to exclude companies in the CXO sector, thereby concentrating on the upstream innovative drug industry [1] Group 3 - The innovative drug sector's fundamentals are gradually improving, making it a worthwhile area for attention despite uncertainties surrounding overseas policies [1] - The offshore Hong Kong market is expected to benefit from rising expectations of interest rate cuts by the Federal Reserve, enhancing the attractiveness of the Hang Seng Innovative Drug ETF [1] - The ETF offers significant scale, good liquidity, and supports T+0 trading, positioning it as an effective tool for investors to capitalize on opportunities in the Hong Kong innovative drug sector [1]
创新药审评审批提速落地！创新药板块整体回暖 恒生创新药ETF(520500)昨日逆势加仓1.27亿 成交额环比增长94%
Xin Lang Ji Jin·2025-09-12 08:02